Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia

Psychological Medicine

Volumn 40, Issue 8, 2010, Pages 1337-1347

  Ringen, P A ^a,b   Vaskinn, A ^b   Sundet, K ^a   Engh, J A ^a,c   Jonsdottir H ^a,c   Simonsen, C ^a,c   Friis, S ^a,c   Opjordsmoen, S ^a,c   Melle, I ^a,c   Andreassen, O A ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bipolar disorder; cannabis; neurocognition; schizophrenia

Indexed keywords

ADULT; ARTICLE; ATTENTION; BIPOLAR DISORDER; CANNABIS ADDICTION; COGNITIVE DEFECT; COMPARATIVE STUDY; DRUG EFFECT; EXECUTIVE FUNCTION; FEMALE; HUMAN; LEARNING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; PSYCHOSIS; SCHIZOPHRENIA; SHORT TERM MEMORY; STATISTICS;

ADULT; ATTENTION; BIPOLAR DISORDER; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMETRICS; PSYCHOMOTOR PERFORMANCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING; YOUNG ADULT;

EID: 77957112078     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291709991620     Document Type: Article

References (54)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn, revised. American Psychological Association: Washington, DC.
2. Brill N, Reichenberg A, Rabinowitz J, Harary E, Lubin G, Davidson M, Weiser M (2007). Accuracy of self-reported premorbid functioning in schizophrenia. Schizophrenia Research 97, 103-108.
3. Cahill CM, Malhi GS, Ivanovski B, Lagopoulos J, Cohen M (2006). Cognitive compromise in bipolar disorder with chronic cannabis use: cause or consequence? Expert Review of Neurotherapeutics 6, 591-598.
4. Cannon-Spoor HE, Potkin SG, Wyatt RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 8, 470-484.
5. Carey KB, Carey MP, Simons JS (2003). Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. Journal of Nervous and Mental Disease 191, 300-308.
6. Cerullo MA, Strakowski SM (2007). The prevalence and significance of substance use disorders in bipolar type I and II disorder. Substance Abuse Treatment, Prevention, and Policy 2, 29.
7. Coulston CM, Perdices M, Tennant CC (2007a). The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia Research 96, 169-184.
8. Coulston CM, Perdices M, Tennant CC (2007b). The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Australian and New Zealand Journal of Psychiatry 41, 869-884.
9. Craddock N, O'Donovan MC, Owen MJ (2006). Genes for schizophrenia and bipolar disorder?Implications for psychiatric nosology. Schizophrenia Bulletin 32, 9-16.
10. Craddock N, Owen MJ (2007). Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry 6, 84-91.
11. Crow TJ (1986). The continuum of psychosis and its implication for the structure of the gene. British Journal of Psychiatry 149, 419-429.
12. Crow TJ (2008). The "big bang" theory of the origin of psychosis and the faculty of language. Schizophrenia Research 102, 31-52.
13. D'souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005). D9-Tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594-608.
14. Daban C, Martinez-Aran A, Torrent C, Tabares-Seisdedos R, Balanza-Martinez V, Salazar-Fraile J, Selva-Vera G, Vieta E (2006). Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychotherapy and Psychosomatics 75, 72-84.
15. Delis D, Kaplan E, Kramer JK (2005). The Delis-Kaplan Executive Function System (D-KEFS). Norwegian Manual Supplement. Pearson Assessment: Stockholm.
16. Delis D, Kramer JH, Kaplan E, Ober BA (2004). California Verbal Learning Test, 2nd edn (CVLT-II). Norwegian Manual Supplement. Pearson Assessment: Stockholm.
17. Eysenck MW, Derakshan N, Santos R, Calvo MG (2007). Anxiety and cognitive performance: attentional control theory. Emotion 7, 336-353.
18. Gottesman II, Gould TD (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry 160, 636-645.
19. Green B, Young R, Kavanagh D (2005). Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry 187, 306-313.
20. Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J (2006). Cannabis use and expression of mania in the general population. Journal of Affective Disorders 95, 103-110.
21. HermanM(2004). Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. International Journal of Mental Health Nursing 13, 282-291.
22. Hugdahl K, Rund BR, Lund A, Asbjornsen A, Egeland J, Ersland L, Landro NI, Roness A, Stordal KI, Sundet K, Thomsen T (2004). Brain activation measured with fMRI during a mental arithmetic task in schizophrenia and major depression. American Journal of Psychiatry 161, 286-293.
23. Ilan AB, Smith ME, Gevins A (2004). Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berlin) 176, 214-222.
24. Ivleva E, Thaker G, Tamminga CA (2008). Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. Schizophrenia Bulletin 34, 734-742.
25. Joyal CC, Halle P, Lapierre D, Hodgins S (2003). Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research 63, 297-299.
26. Kavanagh DJ, Waghorn G, Jenner L, Chant DC, Carr V, Evans M, Hemnan H, Jablensky A, McGrath JJ (2004). Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research 66, 115-124.
27. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
28. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31, 2033-2046.
29. Larsen TK, Friis S, Haahr U, Johannessen JO, Melle I, Opjordsmoen S, Rund BR, Simonsen E, Vaglum PV, McGlashan TH (2004). Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. British Journal of Psychiatry 185, 108-115.
30. Liraud F, Verdoux H (2002). Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale 28, 160-168.
31. Martinez-Aran A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M, Malhi GS, Gonzalez-Pinto A, Daban C, Varez-Grandi S, Fountoulakis K, Kaprinis G, Tabares-Seisdedos R, Yuso-Mateos JL (2007). Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disorders 9, 103-113.
32. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328.
33. Morgan CJ, Curran HV (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. British Journal of Psychiatry 192, 306-307.
34. Murray RM, Morrison PD, Henquet C, Di Forti M (2007). Cannabis, the mind and society: the hash realities. Nature Reviews. Neuroscience 8, 885-895.
35. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CCA, Howie B, Leung HT, Hartmann AM, Moller HJ, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Williams NM, Giegling I, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Gejman PV, Cichon S, Nothen MM, Gill M, Corvin A, Rujescu D, Kirov G, Owen MJ (2008). Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics 40, 1053-1055.
36. Pedersen G, Hagtvet KA, Karterud S (2007). Generalizability studies of the Global Assessment of Functioning-Split version. Comprehensive Psychiatry 48, 88-94.
37. Potvin S, Joyal CC, Pelletier J, Stip E (2008). Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophrenia Research 100, 242-251.
38. Ranganathan M, D'souza DC (2006). The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berlin) 188, 425-444.
39. Ringen PA, Melle I, Birken's AB, Engh JA, F'rden A, Jönsdó ttir H, Nesva?g R, Vaskinn A, Friis S, Larsen F, Opjordsmoen S, Sundet K, Andreassen OA (2007). Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatrica Scandinavica 117, 133-138.
40. Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E, Bechara A (2007). Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophrenia Research 92, 74-84.
41. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, Sachs GS, Nierenberg AA, Thase ME, Pollack MH (2004). Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry 161, 2222-2229.
42. Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Opjordsmoen S, Melle I, Friis S, Andreassen OA (2009). Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophrenia Bulletin. Published online: 14 May 2009. doi :10.1093/schbul/sbp034.
43. Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Hansen CF, Jonsdottir H, Ringen PA, Opjordsmoen S, Friis S, Andreassen OA (2008). Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disorders 10, 245-255.
44. Snyder SH (1973). Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. American Journal of Psychiatry 130, 61-67.
45. Thoma P, Wiebel B, Daum I (2007). Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder. Schizophrenia Research 92, 168-180.
46. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004). Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29, 1363-1373.
47. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L (2009). A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychological Medicine 39, 179-195.
48. Vaskinn A, Sundet K (2001). Estimating pre-morbid IQ: a Norwegian version of National Adult Reading Test. Journal of the Norwegian Psychological Association 38, 1133-1140.
49. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J (1998). Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Research 79, 163-173.
50. Wechsler D (2003). Wechsler Adult Intelligence Scale, 3rd edn (WAIS-III). Norwegian Manual Supplement. Pearson Assessment: Stockholm.
51. Wechsler D (2007). Wechsler Abbreviated Scale of Intelligence (WASI), Norwegian Manual Supplement. Pearson Assessment: Stockholm.
52. Wechsler D (2008). Wechsler Memory Scale (WMS-III). Norwegian Manual Supplement. Pearson Assessment: Stockholm.
53. Weiss RD, Najavits LM, Greenfield SF, Soto JA, Shaw SR, Wyner D (1998). Validity of substance use self-reports in dually diagnosed outpatients. American Journal of Psychiatry 155, 127-128.
54. Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P, Caspari D (2007). Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 257, 203-210.